Abstract: The invention provides isolated nucleic acids molecules, designated DHDR nucleic acid molecules, which encode novel DHDR-related dehydrogenase molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing DHDR nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DHDR gene has been introduced or disrupted. The invention still further provides isolated DHDR proteins, fusion proteins, antigenic peptides and anti-DHDR antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
Type:
Application
Filed:
December 10, 2008
Publication date:
April 15, 2010
Applicant:
Millennium Pharmaceuticals, Inc. Intellectual Property Group
Inventors:
Rachel Meyers, William James Cook, Mark Williamson, Laura A. Rudolph-Owen, Ruth Gimeno
Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
Type:
Application
Filed:
March 10, 2006
Publication date:
August 20, 2009
Applicants:
Millennium Pharmaceuticals, Inc. Intellectual Property Group, Amgen, Inc.